Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women

Pulsed electromagnetic fields on postmenopausal osteoporosis in southwest China: A randomized, active‐controlled clinical trial

“…Bisphosphonates are currently the most commonly prescribed medications for osteoporosis [Strampel et al, 2007]. Among them, alendronate has been shown to be very effective in the prevention and treatment of postmenopausal osteoporosis (PMO) [Felsenberg et al, 1998; Hosking et al, 1998]. On the other hand, complications such as upper gastrointestinal adverse events, renal toxicity, influenza‐like illness, and osteonecrosis of the jaw have drawn much attention and are possible reasons for poor patient compliance [Strampel et al, 2007].…”

“Bis-phossy jaws” – High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw

“…In addition, BPs are useful for other osteoclast-mediated diseases such as osteoporosis and Paget's disease of bone. Randomised trials of BPs have reported a low incidence of side effects and good tolerability (Felsenberg et al, 1998;Rosen et al, 2004). However, some of the less-frequent side effects may have serious implications for affected patients, such as uveitis and scleritis, serious gastrointestinal lesions, renal failure, transient fever, rapid and transient drop in serum calcium (Adami and Zamberlan, 1996) and focal osteomalacia (Boyce et al, 1984).…”

A revision in the definition of osteoporosis

“…One can reasonably infer that most of the internal bone problems on osteoporotic patients are not easy to detect using the currently available diagnostic methods, such as bone densitometry or biochemical markers, available to clinicians at present. Most cases of osteoporotic patients' frailty syndrome-which is possibly caused by internal bone problems-have to be treated with antiresorptive or osteoanabolic agents; known to effectively reduce the risk of osteoporotic fractures based on long-term prospective studies [10][11][12][13][14][15][16][17][18] . The weakness of implementating a more personalized pharmaceutical treatment on osteoporotic patients with internal bone problems is obvious.…”